11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis

11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis

Thyroid Storm: Pathophysiology & Burch-Wartofsky Point Scale

Thyroid storm is an extreme, life-threatening manifestation of thyrotoxicosis characterized by multiorgan decompensation under hypermetabolic adrenergic stress. Mortality approaches 10% to 30% if untreated. Precipitating events include systemic infections, trauma, non-thyroidal surgery, discontinuation of antithyroid medications, diabetic ketoacidosis, pulmonary embolism, toxemia of pregnancy, and exposure to iodinated radiocontrast media.

Clinical Manifestations

Excess circulating free thyroid hormones (thyroxine [$T_4$] and triiodothyronine [$T_3$]) dramatically upregulate myocardial and peripheral beta-adrenergic receptor density and sensitivity. The clinical picture is dominated by hyperadrenergic hyperactivity, severe thermoregulatory failure (hyperpyrexia up to $104\text{ to }106^\circ\text{F} / 40\text{ to }41.1^\circ\text{C}$), tachyarrhythmias (atrial fibrillation with rapid ventricular response in 10–35% of cases), high-output acute decompensated heart failure, extreme agitation, psychosis, delirium, diarrhea, and jaundice from hepatic centrilobular congestion.

Burch-Wartofsky Point Scale (BWPS)

Because serum free $T_4$ and $T_3$ levels do not correlate with clinical severity, thyroid storm is diagnosed clinically using the Burch-Wartofsky Point Scale (BWPS):

                  BURCH-WARTOFSKY POINT SCALE (BWPS) SCORING
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. Thermoregulatory Dysfunction: 99.0–99.9°F (5 pts) ... >=104.0°F (30 pts)│
  │ 2. Central Nervous System Effects: Mild agitation (10 pts), Delirium /      │
  │    Psychosis (20 pts), Seizures / Coma (30 pts)                             │
  │ 3. Gastrointestinal-Hepatic: Diarrhea / Nausea / Vomiting / Pain (10 pts),  │
  │    Unexplained Jaundice (20 pts)                                            │
  │ 4. Cardiovascular Dysfunction:                                              │
  │    • Tachycardia: 99–109 bpm (5 pts) ... >=140 bpm (25 pts)                 │
  │    • Congestive Heart Failure: Mild (5 pts), Moderate (10 pts), Severe (15) │
  │    • Atrial Fibrillation: Present (10 pts)                                  │
  │ 5. Precipitating Event History: Absent (0 pts), Present (10 pts)            │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ TOTAL SCORE INTERPRETATION:                                                 │
  │   • < 25 Points:  Thyroid Storm Unlikely                                    │
  │   • 25–44 Points: Impending Thyroid Storm                                   │
  │   • >= 45 Points: Highly Suggestive of Overt Thyroid Storm (TREAT STAT!)    │
  └─────────────────────────────────────────────────────────────────────────────┘

---

Quadruple Drug Sequence for Thyroid Storm

Therapy for thyroid storm must be initiated immediately upon clinical recognition. The pharmacotherapy regimen targets four distinct biochemical checkpoints in a strict sequential order.

               QUADRUPLE DRUG SEQUENCE IN THYROID STORM
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ STEP 1: BLOCK NEW HORMONE SYNTHESIS (THIONAMIDE)                            │
  │   • Propylthiouracil (PTU) 500-1,000 mg load, then 250 mg PO/NG q4h         │
  │     --> Blocks thyroid peroxidase AND peripheral 5'-deiodinase (T4 to T3)   │
  │   • OR Methimazole 20 mg PO/NG q4–6h                                        │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ STEP 2: BLOCK HORMONE RELEASE (INORGANIC IODINE)                            │
  │   • SSKI 5 drops PO q6h OR Lugol's Solution 8 drops PO q6h                  │
  │   • CRITICAL RULE: MUST WAIT AT LEAST 1 HOUR AFTER STEP 1!                  │
  │     --> Prevents Jod-Basedow phenomenon; induces Wolff-Chaikoff effect      │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ STEP 3: CONTROL ADRENERGIC HYPERACTIVITY (BETA-BLOCKER)                     │
  │   • Propranolol 60–80 mg PO q4h or 1–2 mg IV q10–15m (blocks peripheral T4->T3)│
  │   • Esmolol IV infusion (load 500 mcg/kg, titrate 50–300 mcg/kg/min)        │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ STEP 4: GLUCOCORTICOID SUPPORT & PERIPHERAL CONVERSION BLOCK                │
  │   • Hydrocortisone 100 mg IV q8h OR Dexamethasone 2 mg IV q6h               │
  │     --> Treats relative adrenal exhaustion + blunts peripheral T4 to T3     │
  └─────────────────────────────────────────────────────────────────────────────┘

Step 1: Block Synthesis (Thionamides)

• Propylthiouracil (PTU): 500 to 1,000 mg loading dose, then 250 mg PO or NG every 4 hours (2016 American Thyroid Association guideline). PTU is historically preferred over methimazole in acute thyroid storm because it uniquely exerts a dual mechanism: it inhibits thyroid peroxidase (blocking organification and iodotyrosine coupling in the thyroid gland) AND directly inhibits peripheral 5'-monodeiodinase, reducing peripheral conversion of $T_4$ to the active $T_3$ by 20% to 30%.
• Methimazole (MMI): 20 mg PO or NG every 4 to 6 hours. Highly effective organification blocker with a longer half-life, but does not block peripheral $T_4$-to-$T_3$ conversion. Methimazole is preferred in uncomplicated thyrotoxicosis and for long-term maintenance because PTU carries an FDA boxed warning for fulminant hepatic necrosis.

Step 2: Block Release (Inorganic Iodine) & The 1-Hour Timing Rule

• Pharmacology: Administer Saturated Solution of Potassium Iodide (SSKI) (5 drops PO/NG every 6 hours) or Lugol's Solution (8 drops PO/NG every 6 hours). Supraphysiologic concentrations of inorganic iodide transiently block the proteolytic cleavage and release of pre-formed $T_4$ and $T_3$ from thyroglobulin and temporarily suppress organification (Wolff-Chaikoff effect).
• The Critical 1-Hour Rule: Inorganic iodine must be administered AT LEAST 1 HOUR AFTER the initial dose of thionamide (PTU or methimazole).
  • The Jod-Basedow Hazard: If inorganic iodine is administered prior to thionamide blockade, the massive influx of exogenous iodine substrate provides fuel for unchecked thyroid peroxidase, stimulating explosive de novo synthesis and release of new thyroid hormones (Jod-Basedow phenomenon), which catastrophically worsens thyroid storm.

Step 3: Beta-Adrenergic Receptor Blockade

• Propranolol: 60 to 80 mg PO every 4 to 6 hours, or 1 to 2 mg slow IV push every 10 to 15 minutes (maximum 10 mg). Non-selective beta-blocker that counteracts tachycardia, tremor, and agitation. At high doses ($>160\text{ mg/day}$), propranolol also inhibits peripheral 5'-deiodinase conversion of $T_4$ to $T_3$.
• Esmolol: Continuous IV infusion (loading dose 500 mcg/kg over 1 minute, followed by maintenance titration at 50 to 300 mcg/kg/min). Ultra-short acting (half-life ~9 minutes); ideal in critically ill patients with borderline hemodynamics, acute decompensated heart failure, or underlying reactive airway disease where rapid titration is critical.

Step 4: Systemic Glucocorticoids

• Hydrocortisone 100 mg IV every 8 hours (or 300 mg initial load, then 100 mg q8h), or Dexamethasone 2 mg IV every 6 hours.
• Glucocorticoids treat relative adrenal exhaustion driven by the hypermetabolic turnover of endogenous cortisol, provide hemodynamic stability, and synergistically inhibit peripheral $T_4$-to-$T_3$ monodeiodination.

Antipyresis & Enterohepatic Elimination

• Acetaminophen: Primary antipyretic of choice for hyperpyrexia.
• Aspirin Contraindication: Aspirin and NSAIDs are strictly contraindicated! Salicylates compete with $T_4$ and $T_3$ for binding sites on thyroid-binding globulin (TBG) and transthyretin, displacing bound thyroid hormones and sharply increasing circulating free, active $T_4$ and $T_3$ concentrations.
• Bile Acid Sequestrants: Cholestyramine 4 g orally four times daily binds thyroid hormones undergoing enterohepatic circulation in the gastrointestinal tract, accelerating fecal excretion and lowering free $T_4$ levels.

---

Myxedema Coma: Pathophysiology & Emergent Pharmacotherapy

Myxedema coma is the extreme fatal culmination of untreated, severe hypothyroidism. It carries a mortality rate of 25% to 50%. The cardinal clinical hallmarks are:

1. Severe Hypothermia: Core body temperature frequently $<95^\circ\text{F} (35^\circ\text{C})$, and often $<90^\circ\text{F} (32.2^\circ\text{C})$.
2. Profound Bradycardia & Hypotension: Decreased cardiac inotropy and chronotropy, pericardial effusions, and decreased systemic vascular resistance.
3. Hypoventilation & Hypercapnia: Blunted ventilatory responses to hypoxia and hypercapnia, macroglossia, and respiratory muscle weakness requiring mechanical ventilation.
4. Neuropsychiatric Deterioration: Stupor, lethargy, delusions ("myxedema madness"), seizures, and coma.

The Mandatory Glucocorticoid Pre-Treatment Rule

Before administering thyroid hormone, clinicians must address the adrenal axis:

• Stress-Dose Hydrocortisone (100 mg IV every 8 hours) must be administered PRIOR TO or SIMULTANEOUSLY WITH intravenous thyroid hormone.
• Pathophysiological Hazard: Administering thyroid hormone increases cellular metabolic rate and accelerates the hepatic clearance of endogenous cortisol. If co-existing primary adrenal insufficiency (autoimmune polyglandular syndrome) or secondary hypopituitarism is present, administering thyroid hormone alone will precipitate acute, fatal circulatory collapse (adrenal crisis).

                  MYXEDEMA COMA PHARMACOTHERAPY SEQUENCE
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. GLUCOCORTICOID SUPPORT (MANDATORY BEFORE OR WITH THYROID HORMONE)        │
  │    • Hydrocortisone 100 mg IV q8h to prevent precipitating adrenal crisis   │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 2. INTRAVENOUS THYROID HORMONE REPLACEMENT                                  │
  │    • Levothyroxine (IV T4): 200–400 mcg IV load, then 50–100 mcg daily     │
  │    • +/- Liothyronine (IV T3): 5–20 mcg IV load, then 2.5–10 mcg q8h       │
  │      --> T3 provides immediate active hormone (5'-deiodinase is impaired)  │
  │      --> Use caution with T3 in elderly or severe coronary artery disease   │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 3. SUPPORTIVE CRITICAL CARE                                                 │
  │    • Passive external rewarming only (active rewarming causes vasodilation) │
  │    • Mechanical ventilation for hypercapnia; D5NS for hypoglycemia/hyponatremia│
  └─────────────────────────────────────────────────────────────────────────────┘

Thyroid Hormone Replacement Strategies

• Intravenous Levothyroxine (T4): Loading dose of 200 to 400 mcg IV, followed by 50 to 100 mcg IV daily until conversion to oral therapy. The large IV loading dose rapidly saturates empty binding sites on thyroid-binding globulin.
• Intravenous Liothyronine (T3): Loading dose of 5 to 20 mcg IV, followed by 2.5 to 10 mcg IV every 8 hours. In severe myxedema coma, the peripheral 5'-deiodinase enzyme that converts $T_4$ to $T_3$ is profoundly downregulated by hypothermia and critical illness. Co-administering $T_3$ provides immediate biologically active hormone. However, in elderly patients or those with coronary artery disease, high doses of $T_3$ can trigger fatal myocardial ischemia or ventricular arrhythmias; doses should be reduced or withheld.
• Rewarming Rule: Use passive rewarming blankets only. Active external rewarming produces peripheral vasodilation, precipitating profound distributive shock.

---

Acute Adrenal Crisis: Emergency Resuscitation

Acute adrenal crisis is a life-threatening state of severe relative or absolute glucocorticoid and mineralocorticoid deficiency. Triggers include septic shock, trauma, surgery, acute myocardial infarction, bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome), or abrupt cessation of chronic exogenous corticosteroid therapy.

Clinical Presentation & Characteristic Electrolyte Pattern

• Refractory Hypotensive Shock: Severe distributive shock unresponsive to aggressive crystalloid volume administration and high-dose vasopressor infusions.
• Gastrointestinal Symptoms: Severe abdominal pain, rigidity, nausea, and vomiting, frequently mimicking an acute surgical abdomen.
• Metabolic Hallmarks: Hyponatremia, Hyperkalemia, Hypoglycemia, and mild non-anion gap metabolic acidosis (due to mineralocorticoid deficiency impairing renal tubular $H^+$ and $K^+$ excretion and causing renal sodium wasting).

                    ACUTE ADRENAL CRISIS RESUSCITATION
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ 1. VOLUME EXPANSION & GLUCOSE CORRECTION                                    │
  │    • 1,000–2,000 mL 5% Dextrose in 0.9% Normal Saline (D5NS) in Hour 1      │
  │    • Corrects intravascular collapse, hyponatremia, and severe hypoglycemia │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 2. DEFINITIVE GLUCOCORTICOID REPLACEMENT                                    │
  │    • Hydrocortisone 100 mg IV bolus, then 200 mg/24h continuous infusion    │
  │      (or 50 mg IV push q6h)                                                 │
  │    • NOTE: >100 mg/day hydrocortisone saturates mineralocorticoid receptors;│
  │      fludrocortisone is NOT required in the acute emergency phase           │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ 3. DO NOT DELAY STEROIDS FOR TESTING                                        │
  │    • Draw a random cortisol and ACTH if possible, then treat at once        │
  │    • Dexamethasone 4 mg IV only if hydrocortisone is unavailable, or when   │
  │      an undiagnosed patient must have a cosyntropin test first              │
  └─────────────────────────────────────────────────────────────────────────────┘

Glucocorticoid Selection & Dosing

1. Hydrocortisone (First-Line): Administer 100 mg IV bolus, followed by 200 mg per 24 hours as a continuous infusion (or 50 mg IV push every 6 hours). At doses $\ge 100\text{ mg/day}$, hydrocortisone provides maximal glucocorticoid coverage and exerts cross-over mineralocorticoid receptor saturation equivalent to 0.1 mg of fludrocortisone. Oral fludrocortisone is unnecessary until hydrocortisone is tapered below 50 mg/day.
2. Never Delay Treatment for Testing: The 2016 Endocrine Society guideline on primary adrenal insufficiency says to give hydrocortisone immediately in suspected adrenal crisis. Draw a random cortisol and ACTH first if this can be done without delay. In a patient with known Addison disease or long-term steroid use, no diagnostic test is needed.
3. Dexamethasone (Limited Role): Dexamethasone 4 mg IV does not cross-react with cortisol immunoassays, so it is sometimes chosen when an undiagnosed patient must have a cosyntropin stimulation test before treatment, or when hydrocortisone is unavailable. It has essentially no mineralocorticoid activity, which matters in primary adrenal insufficiency with hyponatremia and hyperkalemia. Switch to hydrocortisone as soon as testing is done.